New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2013
14:25 EDTSTJ, MRK, PFE, GSK, BSX, LLY, SNY, JNJ, MDT, BMY, AZN, RHHBYDrug, medical device makers must disclose doctor payments, Bloomberg says
Payments from drugmakers and medical device companies to doctors must be disclosed to the U.S. government beginning next March, says Bloomberg. Reference Link
News For RHHBY;JNJ;GSK;AZN;SNY;PFE;BMY;LLY;MRK;MDT;BSX;STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
April 14, 2015
07:50 EDTJNJJohnson & Johnson reports Q1 Worldwide Consumer sales $3.4B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson cuts FY15 adjusted EPS to $6.04-$6.19 from $6.12-$6.27
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q1 domestic sales up 5.9% to $8.69B
Subscribe for More Information
07:45 EDTJNJJohnson & Johnson reports Q1 adjusted EPS $1.56, consensus $1.54
Subscribe for More Information
07:15 EDTAZNFDA Endocrinologic & Metabolic Drugs Advisory Committee holds a meeting
Subscribe for More Information
06:30 EDTRHHBYRoche to seek to have cancer drug tested in 11 trials in 2015, Reuters says
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
April 13, 2015
17:13 EDTMDTIBM Medtronic to partner to improve diabetes care
IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
17:10 EDTMDT, JNJIBM establishes a Watson Health Cloud
Subscribe for More Information
16:21 EDTJNJOn The Fly: Top stock stories for Monday
Subscribe for More Information
15:38 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:12 EDTPFEMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.
15:08 EDTJNJJohnson & Johnson April 100 straddle priced for 2.2% movement into Q1
14:07 EDTJNJEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
13:28 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
11:12 EDTJNJJohnson & Johnson technical notes before earnings
Leading up to earnings, the shares have been trading in a narrow range largely bound by $98 at the low and $103 at the high. This trading range was preceded by a decline from the 52-week high set back in the fall of 2014. In a longer time frame, the current trading action is part of a larger potential topping process, with $95 as the midpoint. On worse than expected news, the low bound at $98 would be first important support. A breakdown below $98 would see next support at $95. A move below $95 would confirm the topping process and break the long-term uptrend. Support below $95 would be at $93.94. If results and outlook are better than expected, first resistance would be at the top of the range at $103. Next resistance would then be at $105.36. A move above that level would see $107.10, and then 52-week high and life high at $109.49 as next potential upside objectives.
10:01 EDTRHHBYRoche acquires CAPP Medical
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.
10:00 EDTSTJOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:58 EDTMRK, AZNMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
08:54 EDTAZNAstraZeneca has negative read through from briefing docs, says SunTrust
Subscribe for More Information
06:33 EDTSTJSt. Jude Medical upgraded to Neutral from Underperform at Credit Suisse
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use